Cargando…

Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia

INTRODUCTION: Across the world, health systems are adopting approaches to manage rising healthcare costs. One common strategy is a medication copayments scheme where consumers make a contribution (copayment) towards the cost of their dispensed medicines, with remaining costs subsidised by the health...

Descripción completa

Detalles Bibliográficos
Autores principales: Seaman, Karla L, Sanfilippo, Frank M, Roughead, Elizabeth E, Bulsara, Max K, Kemp-Casey, Anna, Bulsara, Caroline, Watts, Gerald F, Preen, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577882/
https://www.ncbi.nlm.nih.gov/pubmed/28637723
http://dx.doi.org/10.1136/bmjopen-2016-013691
_version_ 1783260432367091712
author Seaman, Karla L
Sanfilippo, Frank M
Roughead, Elizabeth E
Bulsara, Max K
Kemp-Casey, Anna
Bulsara, Caroline
Watts, Gerald F
Preen, David
author_facet Seaman, Karla L
Sanfilippo, Frank M
Roughead, Elizabeth E
Bulsara, Max K
Kemp-Casey, Anna
Bulsara, Caroline
Watts, Gerald F
Preen, David
author_sort Seaman, Karla L
collection PubMed
description INTRODUCTION: Across the world, health systems are adopting approaches to manage rising healthcare costs. One common strategy is a medication copayments scheme where consumers make a contribution (copayment) towards the cost of their dispensed medicines, with remaining costs subsidised by the health insurance service, which in Australia is the Federal Government. In Australia, copayments have tended to increase in proportion to inflation, but in January 2005, the copayment increased substantially more than inflation. Results from aggregated dispensing data showed that this increase led to a significant decrease in the use of several medicines. The aim of this study is to determine the demographic and clinical characteristics of individuals ceasing or reducing statin medication use following the January 2005 Pharmaceutical Benefit Scheme (PBS) copayment increase and the effects on their health outcomes. METHODS AND ANALYSIS: This whole-of-population study comprises a series of retrospective, observational investigations using linked administrative health data on a cohort of West Australians (WA) who had at least one statin dispensed between 1 May 2002 and 30 June 2010. Individual-level data on the use of pharmaceuticals, general practitioner (GP) visits, hospitalisations and death are used. This study will identify patients who were stable users of statin medication in 2004 with follow-up commencing from 2005 onwards. Subgroups determined by change in adherence levels of statin medication from 2004 to 2005 will be classified as continuation, reduction or cessation of statin therapy and explored for differences in health outcomes and health service utilisation after the 2005 copayment change. ETHICS AND DISSEMINATION: Ethics approvals have been obtained from the Western Australian Department of Health (#2007/33), University of Western Australia (RA/4/1/1775) and University of Notre Dame (0 14 167F). Outputs from the findings will be published in peer reviewed journals designed for a policy audience and presented at state, national and international conferences.
format Online
Article
Text
id pubmed-5577882
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55778822017-09-08 Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia Seaman, Karla L Sanfilippo, Frank M Roughead, Elizabeth E Bulsara, Max K Kemp-Casey, Anna Bulsara, Caroline Watts, Gerald F Preen, David BMJ Open Health Policy INTRODUCTION: Across the world, health systems are adopting approaches to manage rising healthcare costs. One common strategy is a medication copayments scheme where consumers make a contribution (copayment) towards the cost of their dispensed medicines, with remaining costs subsidised by the health insurance service, which in Australia is the Federal Government. In Australia, copayments have tended to increase in proportion to inflation, but in January 2005, the copayment increased substantially more than inflation. Results from aggregated dispensing data showed that this increase led to a significant decrease in the use of several medicines. The aim of this study is to determine the demographic and clinical characteristics of individuals ceasing or reducing statin medication use following the January 2005 Pharmaceutical Benefit Scheme (PBS) copayment increase and the effects on their health outcomes. METHODS AND ANALYSIS: This whole-of-population study comprises a series of retrospective, observational investigations using linked administrative health data on a cohort of West Australians (WA) who had at least one statin dispensed between 1 May 2002 and 30 June 2010. Individual-level data on the use of pharmaceuticals, general practitioner (GP) visits, hospitalisations and death are used. This study will identify patients who were stable users of statin medication in 2004 with follow-up commencing from 2005 onwards. Subgroups determined by change in adherence levels of statin medication from 2004 to 2005 will be classified as continuation, reduction or cessation of statin therapy and explored for differences in health outcomes and health service utilisation after the 2005 copayment change. ETHICS AND DISSEMINATION: Ethics approvals have been obtained from the Western Australian Department of Health (#2007/33), University of Western Australia (RA/4/1/1775) and University of Notre Dame (0 14 167F). Outputs from the findings will be published in peer reviewed journals designed for a policy audience and presented at state, national and international conferences. BMJ Publishing Group 2017-06-21 /pmc/articles/PMC5577882/ /pubmed/28637723 http://dx.doi.org/10.1136/bmjopen-2016-013691 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Health Policy
Seaman, Karla L
Sanfilippo, Frank M
Roughead, Elizabeth E
Bulsara, Max K
Kemp-Casey, Anna
Bulsara, Caroline
Watts, Gerald F
Preen, David
Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
title Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
title_full Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
title_fullStr Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
title_full_unstemmed Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
title_short Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
title_sort impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from western australia
topic Health Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577882/
https://www.ncbi.nlm.nih.gov/pubmed/28637723
http://dx.doi.org/10.1136/bmjopen-2016-013691
work_keys_str_mv AT seamankarlal impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia
AT sanfilippofrankm impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia
AT rougheadelizabethe impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia
AT bulsaramaxk impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia
AT kempcaseyanna impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia
AT bulsaracaroline impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia
AT wattsgeraldf impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia
AT preendavid impactofconsumercopaymentsforsubsidisedmedicinesonhealthservicesuseandoutcomesaprotocolusinglinkedadministrativedatafromwesternaustralia